132 related articles for article (PubMed ID: 35192890)
1. SETD2 Palmitoylation Mediated by ZDHHC16 in Epidermal Growth Factor Receptor-Mutated Glioblastoma Promotes Ionizing Radiation-Induced DNA Damage.
Fan X; Sun S; Yang H; Ma H; Zhao C; Niu W; Fan J; Fang Z; Chen X
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):648-660. PubMed ID: 35192890
[TBL] [Abstract][Full Text] [Related]
2. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
3. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
[TBL] [Abstract][Full Text] [Related]
4. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H
Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
6. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
[TBL] [Abstract][Full Text] [Related]
7. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
8. G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells.
Cetin MH; Rieckmann T; Hoffer K; Riepen B; Christiansen S; Gatzemeier F; Feyerabend S; Schoof M; Schüller U; Petersen C; Mynarek M; Rothkamm K; Kriegs M; Struve N
Radiat Oncol; 2023 Jan; 18(1):19. PubMed ID: 36709315
[TBL] [Abstract][Full Text] [Related]
9.
Wu S; Gao F; Zheng S; Zhang C; Martinez-Ledesma E; Ezhilarasan R; Ding J; Li X; Feng N; Multani A; Sulman EP; Verhaak RG; de Groot JF; Heffernan TP; Yung WKA; Koul D
Clin Cancer Res; 2020 Mar; 26(6):1395-1407. PubMed ID: 31852834
[TBL] [Abstract][Full Text] [Related]
10. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
[TBL] [Abstract][Full Text] [Related]
11. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Uhm JH; Ballman KV; Wu W; Giannini C; Krauss JC; Buckner JC; James CD; Scheithauer BW; Behrens RJ; Flynn PJ; Schaefer PL; Dakhill SR; Jaeckle KA
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):347-53. PubMed ID: 20510539
[TBL] [Abstract][Full Text] [Related]
14. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.
Stockhausen MT; Kristoffersen K; Stobbe L; Poulsen HS
Cancer Biol Ther; 2014 Feb; 15(2):216-24. PubMed ID: 24525857
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells.
Thomas C; Ely G; James CD; Jenkins R; Kastan M; Jedlicka A; Burger P; Wharen R
Acta Neuropathol; 2001 Jun; 101(6):605-15. PubMed ID: 11515790
[TBL] [Abstract][Full Text] [Related]
17. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Eller JL; Longo SL; Hicklin DJ; Canute GW
Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
[TBL] [Abstract][Full Text] [Related]
19. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
Aguila B; Morris AB; Spina R; Bar E; Schraner J; Vinkler R; Sohn JW; Welford SM
Cancer Lett; 2019 Oct; 462():33-42. PubMed ID: 31377205
[TBL] [Abstract][Full Text] [Related]
20. Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma.
Lu H; Zhang B; Xie Y; Zhao W; Han W; Zhou L; Wang Z
Invest New Drugs; 2023 Aug; 41(4):564-578. PubMed ID: 37322389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]